RxDoctor Payments Data

John Brownell, MD

Family Medicine · Cedar Rapids, IANPI 1861452633

Payments from drug & device makers

$5,472in general payments, 2019–2025

Across 370 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$834
  • Pfizer$737
  • AbbVie$618
  • Novo Nordisk$313
  • Amgen$234
  • Otsuka America Pharmaceutical, Inc.$229
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$5,452100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,472 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$224,869
Medicare patients
514
Services billed
3,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide407$485,361
OzempicSemaglutide148$211,160
JardianceEmpagliflozin215$202,860
FarxigaDapagliflozin Propanediol92$127,006
TrulicityDulaglutide57$79,798
EliquisApixaban69$71,445
WegovySemaglutide21$28,992
RybelsusSemaglutide15$23,739
LinzessLinaclotide29$21,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,365
XareltoRivaroxaban18$19,469
VraylarCariprazine Hcl12$17,454
Tresiba Flextouch U-100Insulin Degludec22$16,339
MyrbetriqMirabegron20$14,978
Emgality PenGalcanezumab-Gnlm18$14,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$168$565,159464 claims
Novo NordiskOzempic, Wegovy, Rybelsus$313$263,891184 claims
Boehringer IngelheimJardiance$191$202,860215 claims
AstraZenecaFarxiga$834$127,00692 claims
PfizerEliquis$737$71,44569 claims
AbbVieLinzess, Vraylar$618$38,88241 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$141$31,39357 claims
Johnson & JohnsonXarelto$81$19,46918 claims
Astellas Pharma US IncMyrbetriq$103$14,97820 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$90$6,60512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →